Clinical trials: Influenza Virus Infection
Influenza, Influenza Vaccines
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to < 18 years of age.
- Trial name
- NCT01310413
- Testing
- Influenza A (H5N1) Virus monovalent vaccine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children
The purpose of the present study is to assess the immunogenicity and safety of vaccine GSK2321138A in children.
- Trial name
- NCT00985790
- Testing
- Influenza vaccine GSK2321138A, Fluarix™
- Where
- 2 sites in Mexico
- Volunteers
- 599 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males
This study is a randomized, double-blind, ascending dose, placebo-controlled, incomplete crossover, single and multiple dose study in healthy Japanese male subjects to assess the pharmacokinetics and safety/tolerability of single…
- Trial name
- NCT01428479
- Testing
- GR121167 Solution
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
- Trial name
- NCT01999842
- Testing
- Investigational H7N9 vaccine GSK3206641A, Investigational H7N9 vaccine GSK3206640A
- Where
- 8 sites in United States, Canada
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza
A multi-centre, randomized, placebo controlled, trial. Participants will be patients either ≥65 years or with one or more high risk conditions presenting to one of four academic emergency departments in Edmonton or Calgary with…
- Trial name
- NCT02561169
- Testing
- Oseltamivir
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- McMaster University
Influenza
Drug Use Investigation for Arepanrix® (H1N1)
This post-marketing surveillance study is designed to collect safety information such as post-vaccination adverse events and adverse reactions from recipients of Arepanrix® (H1N1) Intramuscular Injection.
- Trial name
- NCT02069496
- Testing
- Arepanrix®
- Volunteers
- 3,405 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seasonal Influenza Vaccination
Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions
The objective of this study was to assess the feasibility and effectiveness of using a statewide immunization information system (IIS) to send seasonal influenza vaccine reminders from Local Health Departments (LHDs), targeting…
- Trial name
- NCT01431183
- Testing
- Mailed influenza vaccination reminder notice
- Where
- United States
- Volunteers
- 3,618 people
- Sponsor
- University of Michigan
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.
- Trial name
- NCT01776554
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 12 sites in United States, Thailand
- Volunteers
- 662 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Healthy
Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children
The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) administered as a single intramuscular injection.
- Trial name
- NCT02263131
- Testing
- IL-YANG FLU Vaccine Prefilled Syringe INJ., VAXIGRIP Prefilled Syringe INJ.
- Volunteers
- 416 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Influenza
Study of the Ability of a Flu Vaccine to Prevent Flu Infection
The purpose of this study is to evaluate how effective the vaccine is at preventing subjects developing flu symptoms after they are directly exposed to flu virus.
- Trial name
- NCT00349037
- Testing
- Trivalent DNA vaccine with and without pPJV2012 administered by PMED
- Where
- United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- PowderMed
HIV Infections
H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients
The overall goal of this study is to study influenza vaccine responses in HIV infected individuals. Immunocompromised individuals require special protection from influenza, but may not respond appropriately to the standard killed…
- Trial name
- NCT01111162
- Testing
- H1N1 vaccination
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Pennsylvania
Diabetes Mellitus, Type 2, Influenza
Information-Based Interventions for Influenza Vaccination Among Older Adults With Diabetes in Yangzhou, China
Influenza can cause serious illness in older adults, particularly those with diabetes. Although influenza vaccination is an important preventive measure, vaccination uptake among older adults in China remains low.
- Trial name
- NCT07901673
- Testing
- Standard Information Intervention, Gain-Framed Information Intervention, Loss-Framed Information Intervention
- Where
- 4 sites in China
- Volunteers
- 759 people
- Sponsor
- Southeast University, China
SARS CoV 2 Infection, Influenza, Human
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults…
- Trial name
- NCT05981846
- Testing
- BIMERVAX, SIIV
- Where
- 8 sites in Spain
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Influenza
Influenza Vaccination in the Emergency Department
Randomized controlled trial of influenza vaccination versus referral for vaccination in the Emergency department. Is the Emergency Department an effective venue for vaccination for influenza? Does vaccination for influenza in the…
- Trial name
- NCT00822627
- Testing
- Influenza Vaccination, Education and referral
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Influenza
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' influenza vaccine in children aged 3 to 17 years.
- Trial name
- NCT01379937
- Testing
- Influenza vaccine GSK1562902A Formulation 1, Influenza vaccine GSK1562902A Formulation 2, Havrix™
- Where
- 2 sites in Philippines
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate an Influenza Vaccine Candidate
The purpose of this study is to evaluate the immune response and safety of influenza vaccine candidate with or without adjuvant compared to Fluarix™ administered intramuscularly in elderly aged 60 years old and above.
- Trial name
- NCT00321373
- Testing
- Candidate Influenza Vaccine GSK1247446A - 2 different formulations, FluarixTM
- Where
- 17 sites in Finland, Greece
- Volunteers
- 1,220 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older
The primary efficacy objective is to demonstrate the efficacy of aCoV2 versus a placebo to prevent the first occurrence of virologically-confirmed symptomatic COVID 19 according to the European Centre for Disease Prevention and…
- Trial name
- NCT04806529
- Testing
- Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seqirus
Healthy Volunteers, Influenza
Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines
Background: Seasonal influenza is a major health problem whose impact is typically reduced by vaccination. The H1N1 (swine flu) influenza virus is an emerging pathogen that has the potential to cause devastating illness and even…
- Trial name
- NCT01191853
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza- health-related outcomes of people with COVID-19 or influenza (influenza only included in updated study analyses) the potential effects of…
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT05160636
- Testing
- COVID-19 Vaccine
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- Pfizer
Influenza, Pregnancy
Influenza Vaccine in Pregnancy Part 2
Pregnant women have limited knowledge regarding influenza, its implications during pregnancy, and recommendations for vaccination during pregnancy.
- Trial name
- NCT00593970
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.